Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02831959 · ClinicalTrials.gov registry record · Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
A Phase 3 study, sponsored by NovoCure.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
NCT02831959 is a Phase 3 study that has completed, run by NovoCure. The registered enrollment target is 298 participants.
The verdict
NCT02831959, a Phase 3 study, has completed, sponsored by NovoCure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
Study Summary
The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 inoperable brain metastasis or 2-10 brain metastases, treated with NovoTTF-200M and supportive treatment compared to supportive treatment alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Interventions
- DEVICE NovoTTF-200M device
- OTHER Best Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2016-07 |
| Est. Completion | 2024-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02831959
The ClinicalTrials.gov registry entry for NCT02831959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovoCure, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NovoTTF-200M device is the first listed.
NCT02831959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02831959 about?
NCT02831959 is a clinical study titled "Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).". The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 inoperable brain metastasis or 2-10 brain metastases, treated with NovoTTF-200M and supportive treat...
What is the current status of trial NCT02831959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2016-07. Estimated completion is 2024-11-29.
What interventions are being tested in trial NCT02831959?
The interventions under investigation include: NovoTTF-200M device (DEVICE), Best Standard of Care (OTHER).
Who is sponsoring clinical trial NCT02831959?
This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.